Calaspargase pegol

Drug Profile

Calaspargase pegol

Alternative Names: EZN-2285; Oncaspar-IV; SC-PEG asparaginase; SC-PEG E. coli L-asparaginase; Scalasparagase pegol

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Children's Oncology Group; Dana-Farber Cancer Institute; National Cancer Institute (USA); Shire; Sigma-Tau Pharmaceuticals
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia
  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 28 Apr 2016 Phase-I clinical trials in Acute myeloid leukaemia (IV)
  • 12 May 2015 Baxter BioScience acquires calaspargase pegol from Sigma-Tau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top